Enalare Therapeutics
30 yrs of experience as a buy-side analyst, portfolio manager, private equity investor and investment banker. Currently focuses on providing CEOs and CFOs with strategic advice on key investor issues. Former Board member of The Medicines Co. and Vaxart. MBA Stanford School of Business, BA Yale University.
This person is not in the org chart
This person is not in any offices
Enalare Therapeutics
Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.